Program

Registration

Lobby Area, Exhibit Hall C
10:00 a.m.-8:00 p.m.

Educational Session 1
Predictive Biomarkers: Challenges in Measuring and Using the Targets

Chairperson: Tona M. Gilmer, GlaxoSmithKline, Research Triangle Park, NC, USA
Veteran's Memorial Auditorium
1:30 p.m.-3:30 p.m.

HER2 as a marker for treatment selection in breast cancer
Michael F. Press, USC/Norris Comprehensive Cancer Center, Los Angeles, CA, USA

Targeting ER and HER-2 in breast cancer
Giuseppe Viale, European Institute of Oncology, University of Milan, Milan, Italy

EGFR as a target in oncology: Caveats and pitfalls
Frédérique Penault-Llorca, Société Française du Cancer, Paris, France

Beyond IHC: Quantitative measurement of protein analytes on tissue slides
David L. Rimm, Yale University School of Medicine, New Haven, CT, USA

Educational Session 2
Emerging Targets in Cancer Prevention

Chairperson: Powel H. Brown, UT M.D. Anderson Cancer Center, Houston, TX, USA
Veteran's Memorial Auditorium
3:30 p.m.-5:30 p.m.

Molecular targets of cancer preventive agents
Powel H. Brown

Identifying women who will respond to preventive antiestrogen treatment
Jack Cuzick, Cancer Research UK, Queen Mary University of London, London, England

Metformin to target energy imbalance: Clinical experience in women with early breast cancer
Bernardo Bonanni, European Institute of Oncology, Milan, Italy

Identifying targets for breast and ovarian cancer prevention
Karen A. Johnson, National Cancer Institute-DCP, Bethesda, MD, USA

Review
Scott M. Lippman, UT M.D. Anderson Cancer Center, Houston, TX, USA

Networking Reception

Grand Ballroom, Sheraton Boston Hotel
5:30 p.m.-7:00 p.m.

Continental Breakfast

Boylston Steet Hallway
7:00 a.m.-8:00 a.m.

Opening Remarks

Veteran's Memorial Auditorium
8:00 a.m.-8:05 a.m.

Lewis C. Cantley, Beth Israel Deaconess Medical Center, Boston, MA, USA
James H. Doroshow, National Cancer Institute-DCTD, Bethesda, MD, USA
Ahmad Awada, Institut Jules Bordet, Brussels, Belgium

Keynote Presentations

Chairperson: Lewis C. Cantley, Beth Israel Deaconess Medical Center, Boston, MA, USA
Veteran's Memorial Auditorium
8:05 a.m.-10:05 a.m.

Lessons from resistance to targeted agents
Charles L. Sawyers, Memorial Sloan-Kettering Cancer Center, New York, NY, USA

Identifying tumour-specific targets: The role of clinical translational data
A. Hilary Calvert, University College London Partners, London, England

Break

Boylston Steet Hallway
10:05 a.m.-10:30 a.m.

Plenary Session 1
Drug Responses in Genetically-Engineered Mouse Models for Cancer

Chairperson: Pier Paolo Pandolfi, Beth Israel Deaconess Medical Center, Boston, MA, USA
Veteran's Memorial Auditorium
10:30 a.m.-12:30 p.m.

The co-clinical trial project
Pier Paolo Pandolfi

The use of genetically engineered mouse lung cancer models for testing of novel therapeutics
Kwok-Kin Wong, Dana-Farber Cancer Institute, Boston, MA, USA

Drug resistance and tumor maintenance in genetically engineered mice
Scott W. Lowe, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, USA

PI3 kinases in cancer: Determining the roles of individual PI3K isoforms
Thomas M. Roberts, Dana-Farber Cancer Institute, Boston, MA, USA

Poster Session A / Exhibit Show

Exhibit Halls C-D
12:30 p.m.-2:30 p.m.

Networking Session for Young Investigators

Presented by the AACR-Women in Cancer Research
Chairpersons: Simone Fulda, University of Ulm Children's Hospital, Ulm, Germany; Roya Khosravi-Far, Beth Israel Deaconess Medical Center, Boston, MA, USA; and Sonya D. Zabludoff, AstraZeneca R&D Boston, Boston, MA, USA
Back Bay C, Sheraton Boston Hotel
1:00 p.m.-2:30 p.m.

This inaugural "Bring Your Own Lunch" roundtable session is open to early-career scientists, defined as graduate students, postdoctoral or clinical fellows, or medical students, and residents. There will be a keynote presentation by Joan S. Brugge of Harvard Medical School, followed by the opportunity to meet in small groups with senior scientists from around the world. Confirmed mentors and roundtable topics include:

• Balancing family life and work, Lynda Chin, Dana-Farber Cancer Institute, Boston, MA, USA
• Careers in government, Karen A. Johnson, National Cancer Institute-DCP, Bethesda, MD, USA
• Careers in industry, Frederic J. de Sauvage, Genentech, Inc., South San Francisco, CA, USA and Juliane M. Jürgensmeier, AstraZeneca R&D, Macclesfield, England
• Getting your paper published, Roya Khosravi-Far
• Grant writing, Eileen P. White, The Cancer Institute of New Jersey, New Brunswick, NJ, USA
• Jumpstarting a translational research career, Caroline Dive, Paterson Institute for Cancer Research, University of Manchester, Manchester, England
• Mentoring and supervising, Scott W. Lowe, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, USA and Victoria M. Richon, EpiZyme, Inc., Cambridge, MA, USA
• The path leading to clinical trials, Lillian L. Siu, Princess Margaret Hospital, Toronto, ON, Canada

Plenary Session 2
Targeting the PI3K Pathway

Chairperson: Lewis C. Cantley, Beth Israel Deaconess Medical Center, Boston, MA, USA
Veteran's Memorial Auditorium
2:30 p.m.-4:30 p.m.

Targeting the PI3K pathway in cancer
William Sellers, Novartis Institutes for BioMedical Research, Cambridge, MA, USA

Growth control by the mTOR pathway
David M. Sabatini, MIT Whitehead Institute for Biomedical Research, Cambridge, MA, USA

Targeting PI3K isoforms in cancer
Jean J. Zhao, Dana-Farber Cancer Institute, Boston, MA, USA

Finding biomarkers of resistance to EGFR-targeted therapy in cancer
René Bernards, The Netherlands Cancer Institute, Amsterdam, Netherlands

Special Lecture

Chairperson: Lewis C. Cantley, Beth Israel Deaconess Medical Center, Boston, MA, USA
Veteran's Memorial Auditorium
4:30 p.m.-5:00 p.m.

Therapeutic targeting of ERK signaling: Why is RAF inhibition more effective than MEK inhibition?
Neal Rosen, Memorial Sloan-Kettering Cancer Center, New York, NY, USA

Proffered Paper Session 1

Chairperson: Lewis C. Cantley, Beth Israel Deaconess Medical Center, Boston, MA, USA
Veteran's Memorial Auditorium
5:00 p.m.-5:30 p.m.

Poster Session A / Exhibit Show (continued)

Exhibit Halls C-D
5:30 p.m.-7:30 p.m.

Continental Breakfast

Boylston Steet Hallway
7:00 a.m.-8:00 a.m.

Plenary Session 3
Acquired Drug Resistance

Chairperson: Carlos L. Arteaga, Vanderbilt-Ingram Cancer Center, Nashville, TN, USA
Veteran's Memorial Auditorium
8:00 a.m.-10:00 a.m.

Lessons learned from acquired resistance to kinase inhibitors in chronic myeloid leukemia
Neil P. Shah, UCSF Comprehensive Cancer Center, San Francisco, CA, USA

Resistance to EGFR inhibitors in lung cancer: Where do we go from here?
Jeffrey A. Engelman, Massachusetts General Hospital, Charlestown, MA, USA

ERBB3 (HER3): Role in HER2-mediated tumorigenesis and resistance to anti-HER2 drugs
Carlos L. Arteaga

Epigenetics of resistance to endocrine therapy
Myles A. Brown, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA

Break

Boylston Steet Hallway
10:00 a.m.-10:30 a.m.

Plenary Session 4
Targeting Tumor Cell Metabolism

Chairperson: Chi Van Dang, Johns Hopkins University School of Medicine, Baltimore, MD, USA
Veteran's Memorial Auditorium
10:30 a.m.-12:30 p.m.

Validating metabolic targets for cancer therapy
Craig B. Thompson, University of Pennsylvania, Philadelphia, PA, USA

Cell death under metabolic stress
Tak W. Mak, University of Toronto, Toronto, ON, Canada

Extracellular matrix control of tumor cell metabolism
Joan Brugge, Harvard Medical School, Boston, MA, USA

Tumor cell metabolism in the response to chemotherapy
Guido Kroemer, Institut Gustave-Roussy, Villejuif, France

Poster Session B / Exhibit Show

Exhibit Halls C-D
12:30 p.m.-2:30 p.m.

Concurrent Sessions 1-4

2:30 p.m.-4:30 p.m.

• In Vivo Imaging of Drug Responses

  Chairperson: David Piwnica-Worms, Washington University School of Medicine, St. Louis, MO, USA
  Ballroom A

  Imaging signal transduction pathways and targeted drug action in vivo
  David Piwnica-Worms

  Detecting tumor responses to treatment using magnetic resonance imaging and spectroscopy
  Kevin M. Brindle, University of Cambridge, Cambridge, England

  Detecting tumor responses to treatment using positron emission tomography
  Sigrid Stroobants, University Hospital Antwerp, Antwerp, Belgium

  Imaging-guided therapy in different tumor models using positron emission tomography (PET) and optical imaging
  Alexandra Winkeler, INSERM-U803, Service Hospitalier Frédéric Joliot, Orsay, France

• Circulating Tumor Cells and Tumor Dormancy

  Chairperson: Johann S. de Bono, Royal Marsden Hospital, Sutton, United Kingdom
  Veteran's Memorial Auditorium

  Circulating tumor cells as targets for cancer therapy
  Klaus Pantel, University Medical Center Hamburg-Eppendorf, Hamburg, Germany

  CTCs as pharmacodynamic and/or predictive biomarkers
  Caroline Dive, Paterson Institute for Cancer Research, University of Manchester, Manchester, England

  Circulating tumor cells as biomarkers in the development of the androgen receptor antagonist, MDV3100
  Howard I. Scher, Memorial Sloan-Kettering Cancer Center, New York, NY, USA

  Circulating tumor cells in anticancer drug development: The way ahead
  Johann S. de Bono

• Handling of Toxicities Related to Targeted Therapies

  Chairperson: Jean-Charles Soria, Institut Gustave-Roussy, Villejuif, France
  Ballroom B

  Dermatologic toxicities to targeted therapies
  Mario E. Lacouture, Northwestern University, Chicago, IL, USA

  Cardiac side effects of targeted therapy: Towards a better dialogue between the oncologist and the cardiologist
  Stephane Ederhy, Saint Antoine Hospital, Paris, France

  VEGF inhibitors and the kidney
  Susan E. Quaggin, University of Toronto, Toronto, ON, Canada

  Gastrointestinal and liver toxicities related to targeted therapies
  Josep Tabernero, Vall d'Hebron Hospital, Barcelona, Spain

• Proof of Concept Clinical Trial Design

  Chairperson: Jaap Verweij, Erasmus University Medical Center, Rotterdam, Netherlands
  Ballroom C

  From preclinical concept to man
  James H. Doroshow, National Cancer Institute-DCTD, Bethesda, MD, USA

  Phase I trials: Limits and limitations in proof of concept
  Jaap Verweij

  Proposals for proof of principle designs in oncology
  Jan Bogaerts, EORTC Data Center, Brussels, Belgium

  Credentialing biomarkers in early phase clinical trials: Crossing the bridge from discovery to validation
  Lillian L. Siu, Princess Margaret Hospital, Toronto, ON, Canada

Proffered Paper Session 2

Chairperson: Ahmad Awada, Institut Jules Bordet, Brussels, Belgium
Veteran's Memorial Auditorium
4:30 p.m.-5:30 p.m.

Poster Session B / Exhibit Show (continued)

Exhibit Halls C-D
5:30 p.m.-7:30 p.m.

NIH Grantee Workshop: Review, Program, and Drug Development

Ballroom A
6:30 p.m.-7:30 p.m.

Changes in peer review and the application process
Suzanne Forry-Schaudies, National Cancer Institute-DCTD, Bethesda, MD, USA

NCI Chemical Biology Consortium
Barbara Mroczkowski, National Cancer Institute-DCTD, Bethesda, MD, USA

Continental Breakfast

Boylston Steet Hallway
7:00 a.m.-8:00 a.m.

Plenary Session 5
The Cancer Genome

Chairperson: Heinz-Herbert Fiebig, Oncotest Institute, Freiburg, Germany
Veteran's Memorial Auditorium
8:00 a.m.-10:00 a.m.

Translational pharmacogenomics
Spyro Mousses, Translational Genomics Research Institute, Scottsdale, AZ, USA

Functionalizing the cancer genome
Lynda Chin, Dana-Farber Cancer Institute, Boston, MA, USA

Future challenges of targeted therapy
Frank McCormick, UCSF Comprehensive Cancer Center, San Francisco, CA, USA

Gene signatures for targeted and cytotoxic agents can guide new anticancer drug development
Heinz-Herbert Fiebig

Break

Boylston Steet Hallway
10:00 a.m.-10:30 a.m.

Plenary Session 6
The Cancer Epigenome

Chairperson: Peter A. Jones, USC/Norris Comprehensive Cancer Center, Los Angeles, CA, USA
Veteran's Memorial Auditorium
10:30 a.m.-12:30 p.m.

Targeted inhibition of chromatin modifying enzymes as cancer therapeutics: The HDAC inhibitor vorinostat and beyond
Victoria Richon, EpiZyme, Inc., Cambridge, MA, USA

Sensitivity and resistance to DNA hypomethylating drugs
Jean-Pierre Issa, UT M.D. Anderson Cancer Center, Houston, TX, USA

Cellular reprogramming: Clues to establishing the cancer epigenome
Stephen B. Baylin, Johns Hopkins University School of Medicine, Baltimore, MD, USA

Cracking chromatin open with DNA methylation inhibitors
Peter A. Jones

Poster Session C / Exhibit Show

Exhibit Halls C-D
12:30 p.m.-2:30 p.m.

Concurrent Sessions 5-8

2:30 p.m.-4:30 p.m.

• Protein Kinase Inhibitors in Cancer Clinical Trials

  Chairperson: Sara A. Courtneidge, Burnham Institute for Medical Research, La Jolla, CA, USA
  Veteran's Memorial Auditorium

  Learnings from an oncogene-selective B-Raf inhibitor
  Gideon Bollag, Plexxikon, Inc., Berkeley, CA, USA

  ALK and EGFR inhibitors in clinical development
  Pasi A. Jänne, Dana-Farber Cancer Institute, Boston, MA, USA

  JAK2 inhibitors in myeloproliferative neoplasms
  Ayalew Tefferi, Mayo Clinic, Rochester, MN, USA

  Clinical development of selective RAF/MEK inhibitors
  David B. Solit, Memorial Sloan-Kettering Cancer Center, New York, NY, USA

• Autophagy

  Chairperson: Eileen P. White, The Cancer Institute of New Jersey, New Brunswick, NJ, USA
  Ballroom A

  Role of autophagy-mediated protein quality control in tumor suppression
  Eileen P. White

  Autophagy as an effector program in senescence
  Masashi Narita, Cancer Research UK, Cambridge, England

  The TSC-mTOR pathway
  Kun Liang Guan, UCSD Moores Cancer Center, La Jolla, CA, USA

  Autophagy and tumor dormancy in ovarian cancer: The role of an imprinted tumor suppressor gene ARHI (DIRAS3)
  Robert C. Bast, Jr., UT M.D. Anderson Cancer Center, Houston, TX, USA

• Monoclonal Antibody Therapies

  Chairperson: Mark X. Sliwkowski, Genentech, Inc., South San Francisco, CA, USA
  Ballroom B

  Two-in-one antibody: Herceptin variants that target HER2 and VEGF
  Germaine Fuh, Genentech, Inc., South San Francisco, CA, USA

  Disrupting insulin-like growth factor signaling with monoclonal antibodies
  Douglas Yee, Masonic Cancer Center, University of Minnesota, Minneapolis, MN, USA

  CD47 is an independent prognostic factor and therapeutic antibody target on human AML stem cells
  Ravindra Majeti, Stanford Institute for Stem Cell Biology and Regenerative Medicine, Palo Alto, CA, USA

  Preoperative systemic therapy as a model to probe drug modulation of HER2 in breast cancer
  Luca Gianni, Istituto Nazionale Tumori, Milan, Italy

• Topoisomerase I and II Alpha-specific Inhibitors

  Chairperson: Yves G. Pommier, National Cancer Institute-CCR, Bethesda, MD, USA
  Ballroom C

  3D-QSAR based design of novel inhibitors of topoisomerase II
  Brian B. Hasinoff, University of Manitoba, Winnipeg, MB, Canada

  Repair of topoisomerase II mediated DNA damage: A potential mechanism for targeting specific Top2 isoforms
  John L. Nitiss, St. Jude Children’s Research Hospital, Memphis, TN, USA

  Targeting topoisomerase II inhibitors to cancer cells via the polyamines transport system
  Christian Bailly, Pierre Fabre Research Institute, Toulouse, France

  Novel topoisomerase I inhibitors in development
  Yves G. Pommier

Proffered Paper Session 3

Chairperson: James H. Doroshow, National Cancer Institute-DCTD, Bethesda, MD, USA
Veteran's Memorial Auditorium
4:30 p.m.-5:30 p.m.

Poster Session C / Exhibit Show (continued)

Exhibit Halls C-D
5:30 p.m.-7:30 p.m.

Continental Breakfast

Boylston Steet Hallway
7:00 a.m.-8:00 a.m.

Plenary Session 7
Targeting the Tumor Microenvironment

Chairperson: Kornelia Polyak, Dana-Farber Cancer Institute, Boston, MA, USA
Veteran's Memorial Auditorium
8:00 a.m.-10:00 a.m.

Targeting mechanisms of evasive resistance to anti-angiogenic therapies
Douglas Hanahan, UCSF Comprehensive Cancer Center and Cancer Research Institute, San Francisco, CA, USA

Cancer and inflammation: Common pathways and targets
Frances R. Balkwill, Barts & The London School of Medicine & Dentistry, London, England

Targeting the hedgehog pathway in cancer
Frederic J. de Sauvage, Genentech, Inc., South San Francisco, CA, USA

The pre-metastatic niche: Adapting the foreign soil
David C. Lyden, Weill Medical College of Cornell University, New York, NY, USA

Break

Boylston Steet Hallway
10:00 a.m.-10:30 a.m.

Plenary Session 8
Using Drug Combinations in Targeted Therapy

Chairperson: Scott Powers, Cold Spring Harbor Laboratory, Woodbury, NY, USA
Veteran's Memorial Auditorium
10:30 a.m.-12:30 p.m.

Combination therapy with MEK inhibitors: Moving synergy to the clinic
Peter F. Lebowitz, GlaxoSmithKline, Collegeville, PA, USA

Genome-wide RNAi screens as a tool to develop new combination therapeutic strategies
Scott Powers

Synthetic lethal approaches to the development of new therapies targeting DNA repair deficiencies in cancer
Alan Ashworth, Institute for Cancer Research, London, England

Modeling genotype-associated sensitivity to anti-cancer agents in tumor-derived cell lines
Jeffrey Settleman, Massachusetts General Hospital Cancer Center, Charlestown, MA, USA

Closing Remarks / Adjourn

Veteran's Memorial Auditorium
12:30 p.m.-12:45 p.m.

Lewis C. Cantley, Beth Israel Deaconess Medical Center, Boston, MA, USA